miR-135b-5p/PDE3B轴通过表皮-介质细胞转换调节胰腺癌中杰米西塔抗性的作用
Yuxuan Fu1,2, Liangsheng Chen1,2, Neng Lv1,2
1Postgraduate Training Base Alliance of Wenzhou Medical University (Zhejiang Cancer Hospital), Hangzhou, Zhejiang, China.
Molecular carcinogenesis
|April 2, 2025
概括
在胰腺癌 (PC) 中,gemcitabine耐药性是由miR-135b-5p驱动的,miR-135b-5p针对PDE3B. 恢复PDE3B可以克服这种抵抗并抑制癌细胞过渡,提供新的治疗策略.
科学领域:
- 在瘤学瘤学.
- 分子生物学分子生物学
- 生物化学 生物化学
背景情况:
- 吉姆西塔宾化疗是胰腺癌 (PC) 的标准治疗方法.
- 耐吉他耐药性限制了治疗的有效性和患者的治疗结果.
- 了解耐药机制对于改善PC疗法至关重要.
研究的目的:
- 为了研究胰腺癌中杰姆西塔化学抵抗的分子机制.
- 确定关键的microRNA和参与凝胺耐药性的信号通路.
- 探索miR-135b-5p及其下游目标在PC化学抵抗中的作用.
主要方法:
- 在体外实验改变了PC细胞中的miR-135b-5p水平.
- 用RNA测序来识别与凝素抵抗相关的mRNAs.
- 救援实验验验证PDE3B在化学抵抗和上皮层-介质细胞转换 (EMT) 中的功能.
主要成果:
- 在PC中,miR-135b-5p被确定为凝胺耐药性的关键调节者.
- 证实PDE3B是miR-135b-5p的直接目标.
- 提高PDE3B的调节逆转了miR-135b-5p诱导的化学抵抗,并抑制了EMT.
结论:
- 通过激活EMT,miR-135b-5p/PDE3B信号轴通过激活EMT,促进胰腺癌中的凝抗药性.
- 针对这一轴提供了一种潜在的治疗策略,以克服PC的化学抵抗.
- 这些发现为胰腺癌中凝抗药的分子基础提供了新的见解.
更多相关视频
07:47Author Spotlight: Unveiling Transmembrane Protein Family-Related Markers in Gastric Cancer and Implications for Targeted Therapies
Published on: September 15, 2023
1.4K
09:56Patient-derived Heterogeneous Xenograft Model of Pancreatic Cancer Using Zebrafish Larvae as Hosts for Comparative Drug Assessment
Published on: April 30, 2019
9.1K
相关概念视频
Metastasis
5.5K
Metastasis is the spread of cancer cells from the original site to distant locations in the body. Cancer cells can spread via blood vessels (hematogenous) as well as lymph vessels in the body.
Epithelial-to-Mesenchymal Transition
The epithelial-to-mesenchymal transition or EMT is a developmental process commonly observed in wound healing, embryogenesis, and cancer metastasis. EMT is induced by transforming growth factor-beta (TGF-β) or receptor tyrosine kinase (RTK) ligands, which further...
Epithelial-to-Mesenchymal Transition
The epithelial-to-mesenchymal transition or EMT is a developmental process commonly observed in wound healing, embryogenesis, and cancer metastasis. EMT is induced by transforming growth factor-beta (TGF-β) or receptor tyrosine kinase (RTK) ligands, which further...
5.5K
Mitogens and the Cell Cycle
6.3K
Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
6.3K
mTOR Signaling and Cancer Progression
3.7K
The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
The mTOR pathway or the...
3.7K
Abnormal Proliferation
4.4K
Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the...
4.4K
Drugs that Stabilize Microtubules
2.0K
Microtubules are dynamic structures that undergo cycles of catastrophe and rescue. The microtubules play a central role in cell division by forming the spindle apparatus for segregating the chromosomes. This makes them ideal targets for regulating dividing cells in tumors and malignant cancer cells. Microtubule stabilizing drugs help stabilize the microtubule formation and promote its polymerization. Paclitaxel was the first microtubule stabilizing agent used as anticancer drug in chemotherapy...
2.0K
